These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 29420960

  • 21. Conversion to sirolimus in renal transplant recipients: a single-center experience.
    Yelken B, Caliskan Y, Ozkan O, Gorgulu N, Yazici H, Turkmen A, Sever MS.
    Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial.
    Abdelmalek MF, Humar A, Stickel F, Andreone P, Pascher A, Barroso E, Neff GW, Ranjan D, Toselli LT, Gane EJ, Scarola J, Alberts RG, Maller ES, Lo CM, Sirolimus Liver Conversion Trial Study Group.
    Am J Transplant; 2012 Mar; 12(3):694-705. PubMed ID: 22233522
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
    Herlenius G, Felldin M, Nordén G, Olausson M, Bäckman L, Gustafsson B, Friman S.
    Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
    [Abstract] [Full Text] [Related]

  • 26. Sirolimus as primary immunosuppression is associated with improved coronary vasomotor function compared with calcineurin inhibitors in stable cardiac transplant recipients.
    Raichlin E, Prasad A, Kremers WK, Edwards BS, Rihal CS, Lerman A, Kushwaha SS.
    Eur Heart J; 2009 Jun; 30(11):1356-63. PubMed ID: 19383734
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
    Hüsing A, Schmidt M, Beckebaum S, Cicinnati VR, Koch R, Thölking G, Stella J, Heinzow H, Schmidt HH, Kabar I.
    Ann Transplant; 2015 Nov 26; 20():707-13. PubMed ID: 26608590
    [Abstract] [Full Text] [Related]

  • 31. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.
    J Heart Lung Transplant; 2005 Dec 26; 24(12):2129-36. PubMed ID: 16364861
    [Abstract] [Full Text] [Related]

  • 32. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity.
    Höcker B, Feneberg R, Köpf S, Weber LT, Waldherr R, Wühl E, Tönshoff B.
    Pediatr Transplant; 2006 Aug 26; 10(5):593-601. PubMed ID: 16856996
    [Abstract] [Full Text] [Related]

  • 33. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
    Chang GJ, Mahanty HD, Vincenti F, Freise CE, Roberts JP, Ascher NL, Stock PG, Hirose R.
    Clin Transplant; 2000 Dec 26; 14(6):550-4. PubMed ID: 11127307
    [Abstract] [Full Text] [Related]

  • 34. Long-term experience using CNI-free immunosuppression in selected paediatric heart transplant recipients.
    Rosenthal LM, Nordmeyer J, Kramer P, Danne F, Pfitzer C, Berger F, Schmitt KRL, Schubert S.
    Pediatr Transplant; 2021 Dec 26; 25(8):e14111. PubMed ID: 34405495
    [Abstract] [Full Text] [Related]

  • 35. Tacrolimus with mycophenolate mofetil or sirolimus compared with calcineurin inhibitor-free immunosuppression (sirolimus/mycophenolate mofetil) after heart transplantation: 5-year results.
    Kaczmarek I, Zaruba MM, Beiras-Fernandez A, Reimann R, Nickel T, Grinninger C, Sadoni S, Hagl C, Meiser B.
    J Heart Lung Transplant; 2013 Mar 26; 32(3):277-84. PubMed ID: 23415313
    [Abstract] [Full Text] [Related]

  • 36. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
    Arora S, Ueland T, Wennerblom B, Sigurdadottir V, Eiskjær H, Bøtker HE, Ekmehag B, Jansson K, Mortensen SA, Saunamaki K, Simonsen S, Gude E, Bendz B, Solbu D, Aukrust P, Gullestad L.
    Transplantation; 2011 Jul 27; 92(2):235-43. PubMed ID: 21677600
    [Abstract] [Full Text] [Related]

  • 37. Long-term follow-up of 100 high-risk renal transplant recipients converted from calcineurin inhibitors to sirolimus: a single center experience.
    Halim MA, Al-Otaibi T, Johny KV, Hamid MH, Tawab KA, Balaha MA, Abraham M, Said T, Nair MP, Al-Waheeb S, Al-Muzairai I, Nampoory MR.
    Transplant Proc; 2009 Jun 27; 41(5):1666-70. PubMed ID: 19545704
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial.
    Paoletti E, Amidone M, Cassottana P, Gherzi M, Marsano L, Cannella G.
    Am J Kidney Dis; 2008 Aug 27; 52(2):324-30. PubMed ID: 18585837
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.